HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Glipizide (Glucotrol)

An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Also Known As:

Glucotrol; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glupitel; K-4024; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; Melizide; Mindiab; Minidiab; Minodiab; Ozidia; Pfizer Brand 1 of Glipizide; Pfizer Brand 2 of Glipizide; Glipizide Kenfarma Brand; K 4024; K4024; Glidiazinamide; Glydiazinamide; Glypidizine; Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-

Networked: 215 relevant articles (26 outcomes, 44 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Organic Chemicals: 49
- Sulfur Compounds: 110
  - Sulfones: 130
    - Sulfonylurea Compounds: 29
      - Glipizide: 215
        metaglip

Experts

1.	Korytkowski, Mary T: 2 articles (07/2012 - 05/2004)
2.	Williams, William: 2 articles (11/2006 - 10/2003)
3.	Salzman, Andrew L: 2 articles (11/2006 - 10/2003)
4.	Mikhail, Nasser: 1 article (07/2012)
5.	Donihi, Amy C: 1 article (07/2012)
6.	Deusenberry, Christina M: 1 article (07/2012)
7.	Coley, Kim C: 1 article (07/2012)
8.	Zycband, E: 1 article (04/2012)
9.	Zhu, Y: 1 article (04/2012)
10.	Zhou, Y-P: 1 article (04/2012)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2000 - "Quality of life was improved compared with baseline after 12 weeks' treatment with glipizide GITS 5 to 20 mg/day plus diet in a US double-blind, placebo-controlled trial in 569 patients with type 2 diabetes mellitus. " 12/01/1994 - "Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM." 09/01/2006 - "The aim of this study was to compare the efficacy and tolerability of a sustained-release glipizide (GSR) formulation with those of immediate-release glipizide (GIR) in Chinese patients with type 2 diabetes mellitus. " 09/01/2006 - "Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study." 08/01/1990 - "In the second study, the diurnal glycemic excursions in 8 NIDDM patients chronically and continuously (24 h/day) exposed to glipizide (2.5-7.5 mg 3 times/day) were similar when the drug was taken 30 min before each of the three main meals and when taken immediately before the meals. " Order ALL the reference details at left...
2.	Hyperglycemia 04/01/1995 - "During the course of the treatment and follow-up, hyperglycemia occurred in 6 of 10 subjects in the no treatment group, 6 of 10 in the placebo group, and 2 of 10 in the glipizide treatment group. " 10/01/2005 - "However, despite a salient effect of glipizide on the hyperglycemia of the mice, there was no effect on the time to occlusive thrombus formation (13.2 +/- 0.9 min, n = 4) compared with placebo-treated mice. " 07/01/1995 - "The effect of hyperglycemia on glipizide absorption in NIDDM patients." 01/01/1994 - "A standard dose of the oral sulfonylurea glipizide (200 micrograms/100 g), administered 15 min before a 1-h restraint stress to intact or 80% pancreatectomized rats, produced total suppression of the stress-induced hyperglycemia-hypoinsulinemia, an effect followed by a significant post-stress hypoglycemia of 1 h duration. " 03/01/2000 - "Glipizide and glyburide are effective in controlling hyperglycemia with similar doses in DM2. " Order ALL the reference details at left...
3.	Hypoglycemia (Reactive Hypoglycemia) 06/01/1998 - "This is the first report to describe the delayed onset of hypoglycemia in a child after ingestion of one tablet of glipizide. " 10/01/1980 - "The study of the kinetics of hypoglycemia induced by glipizide (second generation hypoglycemic sulfonamide) was carried out on the normal conscious dog. " 10/01/2011 - "Following the patient's recovery, hypoglycemia recurred and the laboratory tests were repeated, revealing trace amounts of glipizide in her serum and urine. " 05/01/2004 - "This profile of glipizide GITS AM is therapeutically attractive, as it is consistent with the potential for a reduced risk of hypoglycemia." 08/01/2003 - "Glipizide did not affect total pancreatic blood flow, but decreased islet blood flow by 50% in the presence of hypoglycemia. " Order ALL the reference details at left...
4.	Weight Loss (Weight Reduction) 04/01/1985 - "Hypocaloric liquid formula diets were given for one month to 20 moderately obese patients with non-insulin-dependent diabetes mellitus divided into two equal groups; group 1 was treated with weight loss alone; group 2 received glipizide in addition to the hypocaloric diet. " 04/01/2010 - "Sitagliptin was generally well tolerated with a lower risk of hypoglycaemia and weight loss compared with weight gain observed with glipizide." 04/01/2010 - "Relative to baseline, sitagliptin was associated with weight loss (-1.6 kg) compared with weight gain (+0.7 kg) with glipizide. " 03/01/2007 - "Sitagliptin was generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide." 03/01/2007 - "Sitagliptin led to weight loss (change from baseline =-1.5 kg) compared with weight gain (+1.1 kg) with glipizide [between-treatment difference (95% confidence interval) =-2.5 kg (-3.1, -2.0); p < 0.001]. " Order ALL the reference details at left...
5.	Diabetes Mellitus 11/30/1983 - "Our observations show that glipizide therapy is effective in certain patients with noninsulin-dependent diabetes mellitus over a prolonged time period. " 09/13/2006 - "Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies." 03/01/2006 - "Glipizide is a second-generation sulfonylurea commonly used to treat patients with noninsulin-dependent diabetes mellitus. " 06/01/2002 - "Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus." 03/15/1997 - "Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Glyburide (Glibenclamide)
4.	C-Peptide
5.	Lipoproteins (Lipoprotein)
6.	Metformin (Glucophage)
7.	Chlorpropamide
8.	Blood Glucose (Blood Sugar)
9.	glimepiride (Amarel)
10.	repaglinide (Prandin)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Diet Therapy (Therapy, Diet)
3.	Injections
4.	Drug-Eluting Stents
5.	Transplants (Transplant)

blog comments powered by Disqus

TREATMENT OPTIONS
for Type 2 Diabetes Mellitus,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 856 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>